SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0000950142-23-003085
Filing Date
2023-12-29
Accepted
2023-12-29 16:05:34
Documents
3
Group Members
COLUMN GROUP GP, LPCOLUMN GROUP II GP, LPCOLUMN GROUP II, LPCOLUMN GROUP III GP, LPCOLUMN GROUP III, LPCOLUMN GROUP III-A, LPCOLUMN GROUP IV GP, LPCOLUMN GROUP IV, LPCOLUMN GROUP IV-A, LPCOLUMN GROUP MANAGEMENT, LPCOLUMN GROUP OPPORTUNITY III GP, LPCOLUMN

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 6 eh230432395_sc13da6.htm SC 13D/A 380569
2 EXHIBIT 1 eh230432395_ex01.htm EX-99.1 34153
3 EXHIBIT 2 eh230432395_ex02.htm EX-99.2 35546
  Complete submission text file 0000950142-23-003085.txt   452645
Mailing Address 1700 OWENS STREET SUITE 500 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET SUITE 500 SAN FRANCISCO CA 94158 415-865-2050
COLUMN GROUP L P (Filed by) CIK: 0001347769 (see all company filings)

IRS No.: 000000000
Type: SC 13D/A

Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Subject) CIK: 0001426332 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-90978 | Film No.: 231527678
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)